Drew Holzapfel is a Managing Partner at High Lantern Group, with experience in the federal government, pharmaceutical companies including Pfizer, The White House, and US Department of Health and Human Services. He has led initiatives with biopharma companies to advance market readiness, address policy issues, and build strategic partnerships. Drew’s work spans all areas in life sciences and includes significant specialization in Alzheimer’s, mental health, and neuroscience.
